Evidence map›Paper›PMID 33204726›Full record

ArticleBioMed research international2020

Is Lutikizumab, an Anti-Interleukin-1

Ziqin Cao, Yajia Li, Wanchun Wang, Shuo Jie, Xuantao Hu, Jian Zhou, Tong Wu, Dilihumaer Aili, Zeling Long, Yihan Li and 2 more

Open access · hybridAbstract readNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Ziqin CaoDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.ORCID https://orcid.org/0000-0002-2465-5701
Yajia LiDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0003-4710-087X
Wanchun WangDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Shuo JieDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Xuantao HuDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Jian ZhouDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Tong WuDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Dilihumaer AiliDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Zeling LongDepartment of Orthopedic Surgery, Mayo Clinic Rochester, USA.
Yihan LiDepartment of Orthopedic Surgery, University of California, Davis Medical Center, USA.
Pengcheng DouDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.ORCID https://orcid.org/0000-0003-3719-4040
Ren WuDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.ORCID https://orcid.org/0000-0002-4128-2257
Central South University · CNMayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMost guidelines recommend the use of nonsteroidal anti-inflammatory drugs (NSAIDs), duloxetine, and tramadol for the nonoperative treatment of osteoarthritis (OA), but the use of them is limited by the tolerability and safety concerns. Lutikizumab is a novel anti-IL-1

methodsWe conducted a Bayesian network and conventional meta-analyses to compare the efficacy and safety of lutikizumab with other traditional drugs. All eligible randomized clinical trials, in PubMed, CNKI, EMBASE, and Web of Science databases, from January 2000 to January 2020, were included. The Cochrane risk of the bias assessment tool was used for quality assessment. Pain relief, function improvement, and risk of adverse effects (AEs) were compared in this study.

results24 articles with 11858 patients were included. Duloxetine (DUL) had the largest effect for pain relief (4.76, 95% CI [2.35 to 7.17]), and selective cox-2 inhibitors (SCI) were the most efficacious treatment for physical function improvement (SMD 3.94, 95% CI [2.48 to 5.40]). Lutikizumab showed no benefit compared with placebo for both pain relief (SMD 1.11, 95% CI [-2.29 to 4.52]) and function improvement (SMD 0.992, 95% CI [-0.433 to 4.25]). Lutikizumab and all other drugs are of favorable tolerance for patients in the treatment of OA compared with placebo.

conclusionsLutikizumab, the new anti-Interleukin-1

Indexed as

Anti-Inflammatory Agents, Non-SteroidalBayes TheoremCelecoxibCyclooxygenase 2 InhibitorsHumansImmunoglobulinsInterleukin-1alphaInterleukin-1betaOsteoarthritisPainTreatment OutcomeAnti-Inflammatory Agents, Non-SteroidalCelecoxibCyclooxygenase 2 InhibitorsIL1A protein, humanIL1B protein, humanImmunoglobulinsInterleukin-1alphaInterleukin-1betalutikizumab

Identifiers

PMID33204726
PMCPMC7661137
OpenAlexW3095936081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.